


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1 - 18. (Cancelled)

19. (Currently Amended) A conjugate having the general formula



wherein

P represents an N-hydroxypropylmethacrylamide-methacrylate copolymer having a molecular weight of 5-6,000 kDa;

~~NAT represents a nuclide activation therapy agent;~~

NCT represents a neutron capture therapy agent;

L represents a linker moiety capable of linking the polymer to the neutron capture therapy agent;

and

n represents an integer from 1 - 1,000;

and wherein the conjugate further comprises a chemotherapeutic agent attached to the polymer via the linker moiety L.

20. (Previously Presented) A conjugate as claimed in claim 19, wherein the polymer is a 2-hydroxypropylmethacrylamide-methacrylate copolymer.

21. (Currently Amended) A conjugate as claimed in claim 19, wherein the polymer has a molecular weight of 5-100~~7~~
~~preferably 10-70, more preferably 15-45, most preferably 20-40~~
~~ma~~.

22. (Previously Presented) A conjugate as claimed in claim 19, wherein the ratio of hydroxypropylmethacrylamide to methacrylate is from 20:1 to 1:1.

23. (Canceled)

24. (Currently Amended) A conjugate as claimed in claim ~~23~~ 19, wherein the neutron capture therapy agent contains at least one nuclide selected from ^6Li , ^{10}B , ^{22}Na , ^{58}Co , ^{113}Cd , ^{126}I , ^{135}Xe , $^{148\text{m}}\text{Pm}$, ^{149}Sm , ^{151}Eu , ^{155}Gd , ^{157}Gd , ^{164}Dy , ^{184}Os , ^{199}Hg , ^{230}Pa , ^{235}U and ^{241}Pu in sufficient quantity to undergo a neutron capture reaction.

25. (Previously Presented) A conjugate as claimed in claim 24, wherein the nuclide is ^{10}B .

26. (Currently Amended) A conjugate as claimed in claim ~~23~~ 19, wherein ~~NAT~~ NCT represents a boronated amino acid or peptide, a modified carborane cage, a mercaptoborate, a boron-containing porphyrin or phthalocyanine, a boron-containing nucleic acid precursor, or a boron-containing foliate growth factor, hormone, radiation sensitizer, phosphates, phosphonate, phosphoramidates, cyclic thiourea derivative, amine, promazine, hydantoin or barbiturate.

27. (Currently Amended) A conjugate as claimed in claim 19, wherein the ~~NAT agent~~ NCT makes up 1-30%, ~~preferably 5-10%~~, of the overall mass of the conjugate.

28. (Currently Amended) A conjugate as claimed in claim 19, wherein the linker represents a linear or branched C_{1-15} alkyl which may be saturated or unsaturated, optionally substituted by

carbonyl, amide, hydroxyl or halogen; a peptide, ~~preferably 1-10 amino acids in length,~~ in which the amino acids may be further substituted with amino, thio, carboxyl, carboxamide or imidazole groups; or a covalent bond.

29. (Currently Amended) A conjugate as claimed in claim 19, wherein n represents an integer ~~from~~ from 1-500, ~~preferably 1-100, particularly preferably 1-20.~~

30. (Previously Presented)
Poly(HPMA-co-MA-Gly-Phe-Leu-Gly-B SMel)Gly-Phe-Leu-Gly-Paclitaxel
[SEQ ID NO: 20].

31. (Previously Presented)
Poly(HPMA-co-MA-Gly-Phe-Leu-Gly-BSMel)Gly-Phe-Leu-Gly-Doxombicin
[SEQ ID NO: 20].

32. (Previously Presented) A pharmaceutical composition containing the conjugate as claimed in claim 19.

33. (Previously Presented) A method of treating cancer which comprises administering to a patient in need thereof an effective amount of a medicament comprising the conjugate of claim 19.